Reggie Walton. [Image from CorFlow on LinkedIn]CorFlow Therapeutics today announced that it named Reggie Walton as its head of U.S. clinical operations.

雷吉·沃尔顿。【领英网CorFlow图片】CorFlow Therapeutics今天宣布任命ReggieWalton为美国临床运营主管。

The appointment of Walton marks the first U.S. hire for the Switzerland-based maker of a novel diagnostic and drug delivery platform. It comes at a critical time for the company, which just last month brought in $48.5 million to accelerate its novel technology.

沃尔顿的任命标志着这家总部位于瑞士的新型诊断和药物输送平台制造商首次在美国受聘。这对该公司来说是一个关键时刻，就在上个月，该公司投入了4850万美元来加速其新技术的发展。

CorFlow designed its CoFl platform to diagnose microvascular obstruction (MVO) in heart attack patients immediately following stent implantation. It’s also conducting a study for an adaptive platform therapy evaluating the treatment effects of therapeutic agents delivered locally through CoFl system on heart attack patients diagnosed with MVO..

CorFlow设计了其CoFl平台，用于在支架植入后立即诊断心脏病发作患者的微血管阻塞（MVO）。它还在进行一项适应性平台疗法的研究，评估通过CoFl系统局部递送的治疗剂对诊断为MVO的心脏病发作患者的治疗效果。。

“This is a significant moment in CorFlow’s journey as we expand our operations to enable the execution of our pivotal trial and beyond,” CorFlow said of Walton’s appointment in a LinkedIn post. “Reggie holds a Master of Business Administration and a Bachelor of Science in Electrical Engineering and will remain located in Texas with his family.

CorFlow在LinkedIn的一篇帖子中谈到沃尔顿的任命时说：“这是CorFlow旅程中的一个重要时刻，因为我们扩大了业务范围，以便能够执行我们的关键性试验和其他试验。”。“雷吉拥有工商管理硕士学位和电气工程理学学士学位，将与家人一起留在德克萨斯州。

Please join us in welcoming Reggie to our growing team!”.

。

The company said Walton brings “significant expertise” in managing clinical trials in cardiovascular medical devices.

该公司表示，沃尔顿在管理心血管医疗设备的临床试验方面拥有“重要的专业知识”。

Prior to joining CorFlow, Walton spent three years as a clinical operations consultant for Triatletics.io, a company creating tailored analytics solutions for clinical operations leaders and their teams.

在加入CorFlow之前，Walton曾担任Triatletics.io的临床运营顾问三年，Triatletics.io是一家为临床运营领导者及其团队创建量身定制的分析解决方案的公司。

Before that, Walton spent time at some significant players in the cardiovascular device space. He worked at Edwards Lifesciences for more than six years, culminating in a role in clinical operations. After Edwards, Walton served as associate director for clinical operations at Abiomed, which Johnson & Johnson eventually acquired..

在此之前，沃尔顿曾在心血管设备领域的一些重要参与者那里呆过一段时间。他在爱德华兹生命科学公司工作了六年多，最终在临床手术中发挥了重要作用。爱德华兹之后，沃尔顿担任强生最终收购的Abiomed临床运营副总监。。